Phenotypic comparison of common mouse strains developing high-fat diet-induced hepatosteatosis

Molecular Metabolism

Volumn 2, Issue 4, 2013, Pages 435-446

  Kahle, Melanie ^a,c   Horsch, Marion ^a   Fridrich, Barbara ^a,c   Seelig, Anett ^a,c   Schultheiß, Jürgen ^a,c   Leonhardt, Jörn ^a   Irmler, Martin ^a,c   Beckers, Johannes ^a,c,d   Rathkolb, Birgit ^a,b   Wolf, Eckhard ^b   Franke, Nicole ^a,c   Gailus Durner, Valérie ^a   Fuchs, Helmut ^a   de Angelis, Martin Hrabě ^a,c,d   Neschen, Susanne ^a,c  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cancer; Inflammation; Insulin resistance; Non alcoholic fatty liver disease; Oxidative stress; Thyroid metabolism

Indexed keywords

CHOLESTEROL; ESTROGEN RECEPTOR ALPHA; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; HIGH DENSITY LIPOPROTEIN; INTERFERON REGULATORY FACTOR 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TATA BINDING PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CBPA; TRANSCRIPTION FACTOR CTCF; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR GFI; TRANSCRIPTION FACTOR HAND1; TRANSCRIPTION FACTOR NR2E1; TRANSCRIPTION FACTOR NRF1; TRANSCRIPTION FACTOR RORA2; TRANSCRIPTOME; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

129P2/OLAHSD MOUSE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BODY MASS; C3HEB/FE MOUSE; C57BL 6 MOUSE; C57BL/6N MOUSE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; EVOLUTIONARY ADAPTATION; FAT CONTENT; FAT MASS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENOTYPE; GLUCOSE HOMEOSTASIS; INBRED MOUSE STRAIN; INSULIN RESISTANCE; LIPID DIET; LIPID STORAGE; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; UPREGULATION;

MUS;

EID: 84889099952     PISSN: 22128778     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmet.2013.07.009     Document Type: Article

References (61)

1. Milic S., Stimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Digestive Diseases 2012, 30:158-162.
2. Roden M. Mechanisms of disease: hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. Nature Clinical Practice Endocrinology & Metabolism 2006, 2:335-348.
3. Stefan N., Kantartzis K., Haring H.U Causes and metabolic consequences of fatty liver. Endocrine Reviews 2008, 29:939-960.
4. Day C.P. From fat to inflammation. Gastroenterology 2006, 130:207-210.
5. Samuel V.T., Liu Z.X., Qu X., Elder B.D., Bilz S., Befroy D., et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. Journal of Biological Chemistry 2004, 279:32345-32353.
6. Day C.P. The potential role of genes in nonalcoholic fatty liver disease. Clinics in Liver Disease 2004, 8:673-691.
7. Dowman J.K., Tomlinson J.W., Newsome P.N. Pathogenesis of non-alcoholic fatty liver disease. QJM: Monthly Journal of the Association of Physicians 2010, 103:71-83.
8. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
9. Guerrero R., Vega G.L., Grundy S.M., Browning J.D. Ethnic differences in hepatic steatosis: an insulin resistance paradox?. Hepatology 2009, 49:791-801.
10. Rainer J., Sanchez-Cabo F., Stocker G., Sturn A., Trajanoski Z. CARMAweb: comprehensive R- and bioconductor-based web service for microarray data analysis. Nucleic Acids Research 2006, 34:W498-503.
11. Eisen M.B., Spellman P.T., Brown P.O., Botstein D. Cluster analysis and display of genome-wide expression patterns. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:14863-14868.
12. Oliveros, J.C., 2007. VENNY. An interactive tool for comparing lists with Venn Diagrams. Available from:. http://bioinfogp.cnb.csic.es/tools/venny/index.html.
13. Franceschini A., Szklarczyk D., Frankild S., Kuhn M., Simonovic M., Roth A., et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Research 2013, 41:D808-815.
14. Zambelli F., Pesole G., Pavesi G. Pscan: finding over-represented transcription factor binding site motifs in sequences from co-regulated or co-expressed genes. Nucleic Acids Research 2009, 37:W247-252.
15. Gailus-Durner V., Fuchs H., Becker L., Bolle I., Brielmeier M., Calzada-Wack J., et al. Introducing the German Mouse Clinic: open access platform for standardized phenotyping. Nature Methods 2005, 2:403-404.
16. Bradley A., Anastassiadis K., Ayadi A., Battey J.F., Bell C., Birling M.C., et al. The mammalian gene function resource: the international knockout mouse consortium. Mammalian Genome 2012, 23:580-586.
17. Soewarto D., Fella C., Teubner A., Rathkolb B., Pargent W., Heffner S., et al. The large-scale Munich ENU-mouse-mutagenesis screen. Mammalian Genome 2000, 11:507-510.
18. Nolan P.M., Peters J., Strivens M., Rogers D., Hagan J., Spurr N, et al. A systematic, genome-wide, phenotype-driven mutagenesis program for gene function studies in the mouse. Nature Genetics 2000, 25:440-443.
19. Ayadi A., Birling M.C., Bottomley J., Bussell J., Fuchs H., Fray M., et al. Mouse large-scale phenotyping initiatives: overview of the European Mouse Disease Clinic (EUMODIC) and of the Wellcome Trust Sanger Institute Mouse Genetics Project. Mammalian Genome: Official Journal of the International Mammalian Genome Society 2012, 23:600-610.
20. Brown S.D., Moore M.W. The International Mouse Phenotyping Consortium: past and future perspectives on mouse phenotyping. Mammalian Genome 2012, 23:632-640.
21. Neschen S., Morino K., Dong J., Wang-Fischer Y., Cline G.W., Romanelli A.J., et al. n-3 Fatty acids preserve insulin sensitivity in vivo in a peroxisome proliferator-activated receptor-alpha-dependent manner. Diabetes 2007, 56:1034-1041.
22. Fuchs H., Gailus-Durner V., Neschen S., Adler T., Afonso L.C., Aguilar-Pimentel J.A., et al. Innovations in phenotyping of mouse models in the German Mouse Clinic. Mammalian Genome 2012, 23:611-622.
23. Freeman H.C., Hugill A., Dear N.T., Ashcroft F.M., Cox R.D. Deletion of nicotinamide nucleotide transhydrogenase. Diabetes 2006, 55:2153-2156.
24. Nicholson A., Reifsnyder P.C., Malcolm R.D., Lucas C.A., MacGregor G.R., Zhang W., et al. Diet-induced obesity in two C57BL/6 substrains with intact or mutant nicotinamide nucleotide transhydrogenase (Nnt) gene. Obesity 2010, 10:1902-1905.
25. Begriche, K., Massart, J., Robin, M.A., Bonnet, F., and Fromenty, B., 2013. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology (Epub ahead of print). http://dx.doi.org/10.1002/hep.26226.
26. Coulson P.S., Wilson R.A. Portal shunting and resistance to Schistosoma mansoni in 129 strain mice. Parasitology 1989, 3:383-389.
27. Li H., Ji M., Klarmann K.D., Keller J.R. Repression of Id2 expression by Gfi-1 is required for B-cell and myeloid development. Blood 2010, 116:1060-1069.
28. Zeng W.P. All things considered: transcriptional regulation of Th2 differentiation from precursor to effector activation. Immunology 2013, 140:31-38.
29. Meier H., MacPike A.D. Levels and heritability of serum ceruloplasmin activity in inbred strains of mice. Proceedings of the Society for Experimental Biology and Medicine 1968, 1185-1190.
30. Liebelt A.G., Liebelt R.A., Dmochowski L. Cytoplasmic inclusion bodies in primary and transplanted hepatomas of mice of different strains. Journal of the National Cancer Institute 1971, 47:413-427.
31. Dragani T.A., Manenti G., Gariboldi M., De Gregorio L., Pierotti M.A. Genetics of liver tumor susceptibility in mice. Toxicology Letters 1995, 82-83:613-619.
32. Zheng R., Blobel G.A. GATA transcription factors and cancer. Genes & Cancer 2010, 1:1178-1188.
33. Tuteja G., Kaestner K.H. SnapShot: forkhead transcription factors I. Cell 2007, 130:1160.
34. Krawczyk M., Bonfrate L., Portincasa P. Nonalcoholic fatty liver disease. Best Practice & Research Clinical Gastroenterology 2010, 24:695-708.
35. Rohrdanz E., Nguyen T., Pickett C.B. Isolation and characterization of the human glutathione S-transferase A2 subunit gene. Archives of Biochemistry and Biophysics 1992, 298:747-752.
36. Ishii I., Akahoshi N., Yamada H., Nakano S., Izumi T., Suematsu M. Cystathionine gamma-Lyase-deficient mice require dietary cysteine to protect against acute lethal myopathy and oxidative injury. Journal of Biological Chemistry 2010, 285:26358-26368.
37. Maras B., Barra D., Dupre S., Pitari G. Is pantetheinase the actual identity of mouse and human vanin-1 proteins?. FEBS Letters 1999, 461:149-152.
38. Berger J.H., Charron M.J., Silver D.L. Major facilitator superfamily domain-containing protein 2a (MFSD2A) has roles in body growth, motor function, and lipid metabolism. PloS One 2012, 7:e50629.
39. Schönthal A.H. Endoplasmic reticulum stress: its role in disease and novel prospects for therapy. 2012 Scientifica 2012, 26.
40. Wang D., Wie Y., Pagliassotti M.J. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology 2006, 147:943-951.
41. Wie Y., Wang D., Pagliassotti M.J. Saturated fatty acid-mediated endoplasmic reticulum stress and apoptosis are augmented by trans-10, cis-12-conjugated linoleic acid in liver cells. Molecular and Cellular Biochemistry 2007, 303:105-113.
42. Yuan X., Ta T.C., Lin M., Evans J.R., Dong Y., Bolotin E., et al. Identification of an endogenous ligand bound to a native orphan nuclear receptor. PloS One 2009, 4:e5609.
43. Hwang-Verslues W.W., Sladek F.M. HNF4alpha-role in drug metabolism and potential drug target?. Current Opinion in Pharmacology 2010, 10:698-705.
44. Yin L., Ma H., Ge X., Edwards P.A., Zhang Y. Hepatic hepatocyte nuclear factor 4alpha is essential for maintaining triglyceride and cholesterol homeostasis. Arteriosclerosis, Thrombosis, and Vascular Biology 2011, 31:328-336.
45. Forman B.M., Tontonoz P., Chen J., Brun R.P., Spiegelman B.M., Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995, 83:803-812.
46. Jump D.B., Tripathy S., Depner C.M. Fatty acid-regulated transcription factors in the liver. Annual Review of Nutrition 2013, 33:249-269.
47. Deeb S.S., Fajas L., Nemoto M., Pihlajamaki J., Mykkanen L., Kuusisto J., et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nature Genetics 1998, 20:284-287.
48. Miles P.D., Barak Y., He W., Evans R.M., Olefsky J.M. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. Journal of Clinical Investigation 2000, 105:287-292.
49. Barroso I., Gurnell M., Crowley V.E., Agostini M., Schwabe J.W., Soos M.A., et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999, 402:880-883.
50. White D.L., Kanwal F., El-Serag H.B. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clinical Gastroenterology and Hepatology: the Official Clinical Practice Journal of the American Gastroenterological Association 2012, 10(1342-1359):e1342.
51. Licciulli S., Luise C., Scafetta G., Capra M., Giardina G., Nuciforo P., et al. Pirin inhibits cellular senescence in melanocytic cells. American Journal of Pathology 2011, 178:2397-2406.
52. Zhang J., Song M., Wang J., Sun M., Wang B., Li R., et al. Enoyl coenzyme A hydratase 1 is an important factor in the lymphatic metastasis of tumors. Biomedicine & Pharmacotherapy=Biomedicine & Pharmacotherapie 2011, 65:157-162.
53. Li R., Luciakova K., Zaid A., Betina S., Fridell E., Nelson B.D. Thyroid hormone activates transcription from the promoter regions of some human nuclear-encoded genes of the oxidative phosphorylation system. Molecular and Cellular Endocrinology 1997, 128:69-75.
54. Enriquez J.A., Fernandez-Silva P., Garrido-Perez N., Lopez-Perez M.J., Perez-Martos A., Montoya J. Direct regulation of mitochondrial RNA synthesis by thyroid hormone. Molecular and Cellular Biology 1999, 19:657-670.
55. Pillar T.M., Seitz H.J. Thyroid hormone and gene expression in the regulation of mitochondrial respiratory function. European Journal of Endocrinology/European Federation of Endocrine Societies 1997, 136:231-239.
56. Wrutniak-Cabello C., Casas F., Cabello G. Thyroid hormone action in mitochondria. Journal of Molecular Endocrinology 2001, 26:67-77.
57. Brenta G. Why can insulin resistance be a natural consequence of thyroid dysfunction?. Journal of Thyroid Research 2011, 2011:152850.
58. Schneider M.J., Fiering S.N., Thai B., Wu S.Y., Germain E., Parlow A.F., et al. Targeted disruption of the type 1 selenodeiodinase gene (Dio1) results in marked changes in thyroid hormone economy in mice. Endocrinology 2006, 147:580-589.
59. Biddinger S.B., Almind K., Miyazaki M., Kokkotou E., Ntambi J.M., Kahn C.R. Effects of diet and genetic background on sterol regulatory element-binding protein-1c, stearoyl-CoA desaturase 1, and the development of the metabolic syndrome. Diabetes 2005, 54:1314-1323.
60. Simpson E.M., Linder C.C., Sargent E.E., Davisson M.T., Mobraaten L.E., Sharp JJ. Genetic variation among 129 substrains and its importance for targeted mutagenesis in mice. Nature Genetics 1997, 16:19-27.
61. Threadgill D.W., Yee D., Matin A., Nadeau J.H., Magnuson T. Genealogy of the 129 inbred strains: 129/SvJ is a contaminated inbred strain. Mammalian Genome: Official Journal of the International Mammalian Genome Society 1997, 8:390-393.